Targeted delivery of drugs to treat resistant brain tumors
Official title: Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastoma
Funded at Mayo Clinic Jacksonville · NIH-10997330 · Data updated 2026-11-12
This study is exploring a new way to deliver medicine directly to glioblastoma tumors to make treatments work better, and it’s for patients who are dealing with this tough type of brain cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $556,541 |
| NIH project number | 5R01NS129671-03 |
| Project ID | NIH-10997330 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who have shown resistance to standard therapies like Temozolomide.
✕Less likely to help
Patients with glioblastoma who are not resistant to current therapies or those with other types of brain tumors may not benefit from this research.
What this research studies
This research focuses on developing a new method to deliver drugs specifically to glioblastoma tumors, which are known for being resistant to standard treatments. The approach involves using a specialized liposomal formulation that combines a novel drug with existing therapies to enhance their effectiveness. By targeting the tumor more effectively, the goal is to improve patient outcomes and survival rates. The research also investigates the role of a specific protein, Neuroplin-1, in the resistance of these tumors to treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with targeted drug delivery methods in similar contexts, indicating potential for success in this novel approach.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Quinones-Hinojosa, Alfredo — Mayo Clinic Jacksonville
- Study coordinator: Quinones-Hinojosa, Alfredo
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.